With 0.59 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.21 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $4.97 whereas the lowest price it dropped to was $4.44. The 52-week range on BSGM shows that it touched its highest point at $14.11 and its lowest point at $0.23 during that stretch. It currently has a 1-year price target of $10.00. Beta for the stock currently stands at 1.62.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BSGM was down-trending over the past week, with a drop of -27.21%, but this was down by -42.04% over a month. Three-month performance surged to 326.92% while six-month performance rose 362.36%. The stock gained 197.99% in the past year, while it has gained 886.67% so far this year. A look at the trailing 12-month EPS for BSGM yields -0.62 with Next year EPS estimates of -0.17. For the next quarter, that number is -0.04. This implies an EPS growth rate of 66.67% for this year and 32.00% for next year.
Float and Shares Shorts:
At present, 24.25 million BSGM shares are outstanding with a float of 18.89 million shares on hand for trading. On 2025-07-15, short shares totaled 1.18 million, which was 429.0 higher than short shares on 1749772800. In addition to Mr. Ferdinand Groenewald as the firm’s Interim CFO & Principal Accounting Officer, Mr. Karl Henry McPhie serves as its CEO & Director.
Institutional Ownership:
Through their ownership of 0.27128 of BSGM’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, BSGM reported revenue of $0.0 and operating income of -$2984000.0. The EBITDA in the recently reported quarter was -$2779000.0 and diluted EPS was -$0.14.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With BSGM analysts setting a high price target of 10.0 and a low target of 10.0, the average target price over the next 12 months is 10.0. Based on these targets, BSGM could surge 125.23% to reach the target high and rise by 125.23% to reach the target low. Reaching the average price target will result in a growth of 125.23% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.88 being high and -$0.88 being low. For BSGM, this leads to a yearly average estimate of -$0.88.
